Our Focus — Step 2

 
 

Step 2 — Surveying the peaks

Identifying targetable driver alterations

In partnership with academic and clinical collaborators and diagnostic leaders, Elevation Oncology actively evaluates emerging genomic research for true oncogenic driver alterations with a druggable pathway.

“Precise therapy development is needed to ensure that patients and their physicians have treatment options that make their genomic test results actionable.

Dr. Lori Kunkel, Chair of the Scientific Advisory Board
Areas of Interest
  • Identification of emergent genomic alterations of interest due to increased testing and population analysis
  • Novel targeted therapeutic approaches for “rare” (<2% of tumors) clinically relevant alterations
  • Characterization of the mutual exclusivity of driver alterations across tumor types

If you are interested in collaborating to advance the general understanding and clinical relevance of genomic testing for cancer, we would love to hear from you.

Get in touch today at info@elevationoncology.com

Collaborators